News headlines about AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) have been trending somewhat positive this week, according to Alpha One. The research firm, a unit of Accern, identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Alpha One ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AEterna Zentaris earned a daily sentiment score of 0.06 on Alpha One’s scale. Alpha One also gave media stories about the biopharmaceutical company an impact score of 66 out of 100, indicating that recent news coverage is likely to have an impact on the stock’s share price in the near term.
AEterna Zentaris (NASDAQ:AEZS) opened at 0.86 on Friday. AEterna Zentaris has a 12 month low of $0.78 and a 12 month high of $5.59. The company’s 50-day moving average is $2.11 and its 200 day moving average is $2.93. The company’s market cap is $11.61 million.
AEterna Zentaris (NASDAQ:AEZS) last posted its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.02. The firm had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.85 million. AEterna Zentaris had a negative return on equity of 213.27% and a negative net margin of 3,773.91%. The business’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period last year, the company earned ($0.37) earnings per share. Equities analysts forecast that AEterna Zentaris will post ($1.39) earnings per share for the current fiscal year.
Several research firms have recently weighed in on AEZS. Maxim Group restated a “buy” rating and set a $11.00 price objective on shares of AEterna Zentaris in a research report on Thursday, March 30th. Zacks Investment Research cut shares of AEterna Zentaris from a “buy” rating to a “hold” rating in a report on Wednesday, March 8th. Finally, HC Wainwright decreased their target price on shares of AEterna Zentaris from $7.50 to $3.00 and set a “buy” rating for the company in a report on Wednesday, May 10th.
About AEterna Zentaris
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.